Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233454 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Phase 2 study, sponsored by Jason Robert Gotlib.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00233454 is a Phase 2 study that has completed, run by Jason Robert Gotlib. The registered enrollment target is 26 participants.
The verdict
NCT00233454, a Phase 2 study, has completed, sponsored by Jason Robert Gotlib.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
Interventions
- DRUG Midostaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-03 |
| Est. Completion | 2011-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233454
The ClinicalTrials.gov registry entry for NCT00233454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Robert Gotlib, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Midostaurin is the first listed.
NCT00233454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233454 about?
NCT00233454 is a clinical study titled "Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia". The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
What is the current status of trial NCT00233454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2005-03. Estimated completion is 2011-04-16.
What interventions are being tested in trial NCT00233454?
The interventions under investigation include: Midostaurin (DRUG).
Who is sponsoring clinical trial NCT00233454?
This trial is sponsored by Jason Robert Gotlib, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.